Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 12/20 | 0.45 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.34 |
| ▸ | OXTR | P30559 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5783786 | 0.93 | AVPR2 (0.42) | AVPR2AVPR1ASLC6A7OXTRALDH1A1 | |
| SCHEMBL5784602 | 0.92 | AVPR2 (0.49) | AVPR2AVPR1AOXTR | |
| SCHEMBL6475735 | 0.92 | AVPR2 (0.43) | AVPR2AVPR1ANAMPTALDH1A1 | |
| SCHEMBL5785035 | 0.92 | AVPR2 (0.42) | AVPR2AVPR1AOXTR | |
| SCHEMBL6476635 | 0.92 | AVPR2 (0.48) | AVPR2AVPR1ANAMPTOXTRALDH1A1 | |
| SCHEMBL5787756 | 0.91 | AVPR2 (0.41) | AVPR2AVPR1A | |
| SCHEMBL5782086 | 0.90 | AVPR2 (0.46) | AVPR2AVPR1ASLC6A7 | |
| SCHEMBL6486476 | 0.90 | AVPR2 (0.41) | AVPR2AVPR1ASLC6A7POLB | |
| SCHEMBL6476757 | 0.90 | AVPR2 (0.41) | AVPR2AVPR1ASLC6A7POLB | |
| SCHEMBL5785061 | 0.90 | AVPR2 (0.41) | AVPR2AVPR1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900200-B2 | Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2005-05-31 | — | — | US | claimed |
| US-20030018026-A1 | Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2003-01-23 | — | — | US | claimed |
| US-6900200-B2 | Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030018026-A1 | Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018026-A1 | Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | OXTR, OPRL1, HCRTR2 | AVPR2 45/4885AVPR1A 30/4885NAMPT 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.